About ProteinQure
ProteinQure is a company based in Toronto (Canada) founded in 2017 by Tomas Babej, Lucas Siow, Christopher Ing, and Mark Fingerhuth. It operates as a HealthTech. ProteinQure has raised $15 million across 3 funding rounds from investors including Government of Canada, Kensington Capital Partners and Felicis Ventures. The company has 17 employees as of December 31, 2024. ProteinQure offers products and services including PQ203, ProteinStudio™, and Sortilin [SORT1] Delivery System. ProteinQure operates in a competitive market with competitors including Helix, Cyrus Biotechnology, Benchling, Vividion Therapeutics and BioAge Labs, among others.
- Headquarter Toronto, Canada
- Employees 17 as on 31 Dec, 2024
- Founders Tomas Babej, Lucas Siow, Christopher Ing, Mark Fingerhuth
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proteinqure Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15 M (USD)
in 3 rounds
-
Latest Funding Round
$11 M (USD), Series A
May 28, 2025
-
Investors
Government of Canada
& 8 more
-
Employee Count
17
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ProteinQure
ProteinQure offers a comprehensive portfolio of products and services, including PQ203, ProteinStudio™, and Sortilin [SORT1] Delivery System.
A peptide-drug conjugate for advanced metastatic cancer treatment.
A platform for designing novel de novo peptides.
A system for delivering payloads into cancer cells.
People of ProteinQure
Unlock access to complete
Unlock access to complete
Funding Insights of ProteinQure
ProteinQure has successfully raised a total of $15M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $11 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ProteinQure
ProteinQure has secured backing from 9 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Government of Canada, Kensington Capital Partners and Felicis Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in technology startups are made by Felicis Ventures.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage startups
|
Locked | Locked | Locked | |
|
Investments are made in early-stage technology companies by Inovia Capital.
|
Locked | Locked | Locked |
Investor details for ProteinQure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ProteinQure
Investment portfolio details for ProteinQure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ProteinQure
Detailed financials for ProteinQure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proteinqure Comparisons
Peer comparison for ProteinQure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ProteinQure
ProteinQure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helix, Cyrus Biotechnology, Benchling, Vividion Therapeutics and BioAge Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic database for clinical research is provided.
|
|
| Locked | Locked | Locked |
Cloud-based protein-modeling software is developed for drug discovery.
|
|
| Locked | Locked | Locked |
Cloud-based bioinformatics platform is offered for biotech research.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
Detailed competitors of ProteinQure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proteinqure
Complete news archive for ProteinQure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ProteinQure
ProteinQure was founded in 2017 and raised its 1st funding round 2 years after it was founded.
ProteinQure is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Mark Fingerhuth is the current CEO of ProteinQure. They have also founded this company.
ProteinQure is a funded company, having raised a total of $15M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at ProteinQure is 17.
ProteinQure, a clinical-stage biotech company, is engaged in the design of exotic peptides for therapeutic applications. The company leverages its proprietary computational platform, ProteinStudio, to create peptide-drug conjugates for precise tissue- and cell-specific delivery. Solutions are developed for advanced cancer treatments, with the lead program PQ203 currently in Phase 1 clinical trials. Operations span across oncology and precision medicine sectors, aiming to transform treatment approaches through innovative drug delivery systems.
ProteinQure's top competitors include Helix, Vividion Therapeutics and Cyrus Biotechnology.
ProteinQure offers PQ203, ProteinStudio™, and Sortilin [SORT1] Delivery System.
ProteinQure has 9 investors. Key investors include Government of Canada, Kensington Capital Partners, Felicis Ventures, Tom Williams, and Global Founders Capital.